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Abstract Glycation has been implicated in the endothelial dys-
function that contributes to both diabetes- and aging-associated
vascular complications. The aim of the present study was to
determine whether Amadori-glycated phosphatidylethanolamine
(Amadori-PE), a lipid-linked glycation compound that is formed
at an increased rate in hyperglycemic states, a¡ected prolifer-
ation, migration and tube formation of cultured human umbil-
ical vein endothelial cells (HUVEC). Amadori-PE at a low con-
centration of less than 5 WM signi¢cantly enhanced these three
factors involved in angiogenesis. Furthermore, stimulation of
HUVEC with Amadori-PE resulted in secretion of matrix me-
talloproteinase 2 (MMP-2), a pivotal enzyme in the initial step
of angiogenesis. Our results demonstrated for the ¢rst time that
Amadori-PE may be an important compound that promotes
vascular disease as a result of its angiogenic activity on endo-
thelial cells. We also demonstrated that MMP-2 is a primary
mediator of Amadori-PE-driven angiogenesis.
/ 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Proteins react non-enzymatically with glucose, leading to
the production of unstable Schi¡ bases and ultimately Ama-
dori products. These early glycation products are transformed
further into a wide spectrum of compounds termed advanced
glycation end products (AGEs) [1]. Numerous studies have
described the formation and accumulation of Amadori prod-
ucts, such as glycated hemoglobin and serum albumin, and
AGEs, such as carboxymethyllysine and carboxyethyllysine,
in blood and a range of tissues [2^5]. This glycation of protein
progresses during normal aging and at an extremely acceler-
ated rate in patients with diabetes mellitus [6,7]. These
changes have been implicated in the development of diabetic
vascular complications including altered angiogenesis, and
thereby contribute to the disabilities and high mortality rate
found in patients with diabetes [8]. Angiogenesis, the growth
of new vascular capillary channels from preexisting vessels, is
of fundamental importance in pathophysiological events asso-
ciated with diabetes [9]. Recent studies have demonstrated
AGEs initiate angiogenesis and therefore play an active part
in the development and progression of diabetic microangiop-
athy [10^12].
While glycation of proteins has been investigated thor-
oughly, little attention has been paid to glycation of amino-
phospholipids such as phosphatidylethanolamine (PE). Recent
intensive researches on lipid glycation have shown that PE
reacts with glucose to form a Schi¡ base, followed by rear-
rangement to the PE-linked Amadori product shown in Fig. 1
[13^17]. This Amadori product accelerates membrane lipid
peroxidation [17], with its concentration in human erythro-
cytes being proportional to the glycated hemoglobin value
[18]. There is also evidence in rats that the level of Ama-
dori-PE in plasma increases with aging [19]. A recent study
has demonstrated that oxidative stress was directly involved in
the angiogenic response [20]. Amadori-PE is therefore consid-
ered to be a key compound for generating oxidative stress that
disrupts cellular responses and alters cell integrity and surviv-
al. Eventually, Amadori-PE may be one of the origin com-
pounds causing enhancing angiogenesis in vivo. Angiogenesis
normally involves a series of steps including endothelial cell
activation and breakdown of the basement membrane, fol-
lowed by migration, proliferation and tube formation of the
cells. The purpose of this study was to obtain direct evidence
of the e¡ects of Amadori-PE on these key steps of angiogen-
esis using human umbilical vein endothelial cells (HUVEC).
2. Materials and methods
2.1. Materials
1,2-Di(cis-9-octadecenoyl)-sn-glycero-3-phosphoethanolamine (dio-
leoyl-PE) was purchased from Funakoshi (Tokyo, Japan). Amadori-
PE was prepared from a glycation system of dioleoyl-PE/glucose by a
high-performance liquid chromatography technique as described pre-
viously [17]. All other reagents were of analytical grade.
2.2. Cells cultures
HUVEC were purchased from Iwaki (Tokyo, Japan). Cells were
cultured in the growth medium HuMedia-EG21 (Kurabo, Osaka,
Japan), and grown at 37‡C in a humidi¢ed atmosphere of 5% CO2
in air. The HuMedia-EG21 medium consisted of the base medium
(HuMedia-EB21) supplemented with 2% fetal bovine serum (FBS),
0.5 Wg/ml human epidermal growth factor (hEGF), 2 Wg/ml hFGF-B,
5 mg/ml insulin, 50 mg/ml gentamicin and 50 Wg/ml amphotericin B.
Tightly con£uent monolayers of HUVEC, of passage 2 to 6, were
used in the experiments.
2.3. Preparation of Amadori-PE for cell cultures
A portion of 1 mM Amadori-PE in methanol was placed in a sterile
tube and the solvent removed using a N2 gas £ux. The dried Amadori-
PE was dispersed in the culture medium (HuMedia-EG21) using
sonication, followed by dilution with medium to achieve the desired
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¢nal concentration. Medium containing dioleoyl-PE (non-glycated
PE) and sample-free medium were prepared as controls for the study.
2.4. Cell proliferation
HUVEC with 90% con£uent growth were trypsinized, transferred
into 96-well plates (3000 cells/well) and preincubated in HuMedia-
EG21 medium for 24 h. The culture medium was then changed to
a medium containing test samples at various concentrations and in-
cubated for a further 72 h. At the end of these treatments, viable cell
numbers were estimated by the WST-1 assay. Brie£y, 10 Wl of WST-1
solution (Dojindo, Kumamoto, Japan) was added to each well and
incubated at 37‡C for 2 h, and the absorbance at 450 nm of the
cultured medium measured using a microplate reader (Model 550,
Bio-Rad, Tokyo, Japan).
2.5. Migration of HUVEC in a wound closure model
HUVEC were cultured on 12-well plates (2U105 cells/well) in FBS-
free HuMedia-EG21 medium. After 24 h, the cells were scratched
with a yellow pipette tip to obtain a ‘wounded’ monolayer culture
[21]. The media and dislodged cells were aspirated, and fresh medium
added to the plates along with the test samples. After incubation at
37‡C for 12 h, cell migration was observed using a phase contrast
inverted microscope. The width of wounded cells in four randomly
chosen ¢elds was then determined.
2.6. Tube formation
An angiogenesis assay kit (Kurabo) was used according to the
manufacturer’s instructions. Brie£y, HUVEC co-cultured with ¢bro-
blasts were cultivated in the presence or absence of various concen-
trations of Amadori-PE. After 11 days, cells were ¢xed in 70% etha-
nol, and then visualized with van Willebrand factor antibody.
Vascular endothelial growth factor (VEGF, 10 ng/ml) was also tested
as a positive control. Tube length was quanti¢ed using angiogenesis
imaging software (Kurabo).
2.7. Enzyme-linked immunosorbent assays and zymography
HUVEC were cultured on 12-well culture plates (1U105 cells/well)
in HuMedia-EG21 medium containing the test sample at various
concentrations. After 24 h, aliquots of the conditioned medium were
used to measure the levels of matrix metalloproteinases (MMPs) and
VEGF165, using commercial enzyme-linked immunosorbent assay
(ELISA) kits obtained from Biotrak (Amersham-Pharmacia, Frei-
burg, Germany) and RpD Systems (Minneapolis, MN, USA), respec-
tively. The residual conditioned medium was then subjected to gelatin
zymography in order to detect MMP-2.
2.8. Analysis of the expression of MMP-2 by reverse transcriptase-
polymerase chain reaction (RT-PCR)
Total RNA was extracted from the sample-treated HUVEC (1U106
cells) using a commercial kit (RNeasy mini kit, Qiagen, Tokyo, Ja-
pan). The RNA was reverse transcribed to cDNA by addition of
FPLCpure M-MuLV reverse transcriptase (Amersham Biosciences,
Piscataway, NJ, USA) and NotI-d(T)18 primer (Amersham Bioscien-
ces). The MPCR kit (Maxim Biotech, San Francisco, CA, USA) was
used for the ampli¢cation of the cDNA product. PCR thermocycling
was carried out with denaturation at 94‡C for 30 s, and annealing and
extension at 60‡C for 30 s using a Zymoreactor II (ATTO, Tokyo,
Japan). The ampli¢ed cDNA product was then fractionated on a 3%
agarose gel electrophoresis, and stained with SYBR-green I (BMA,
Rockland, ME, USA).
2.9. Statistical analysis
The data are expressed as the mean and S.D. Statistical analysis
was performed using one-way analysis of variance (ANOVA) fol-
lowed by Dunnett’s test. P6 0.05 was accepted as signi¢cant.
3. Results
HUVEC were cultured in the presence or absence of 1 WM
Amadori-PE, and the number of viable cells was evaluated
over 72 h (Fig. 2A). Amadori-PE-treated cells showed an in-
creased proliferation over this time period compared with
control cells cultured without Amadori-PE. This e¡ect was
apparent 12 h after cultivation, with the number of cells
present at 36 h being approximately two-fold greater in the
Amadori-PE culture compared with the control. Non-glycated
dioleoyl-PE induced no change in cell number compared with
the control (Fig. 2A). The enhancing e¡ect of Amadori-PE
on cell proliferation peaked at a concentration of 5 WM
(Fig. 2B,C).
To assess the impact of Amadori-PE on endothelial cell
migration, a denudation injury model was used. Wounded
HUVEC were incubated with Amadori-PE, and the rate of
Fig. 1. Scheme for the glycation of PE. Glucose reacts with an ami-
no group of PE to form an unstable Schi¡ base, which then under-
goes rearrangement to yield the stable deoxy-D-fructosyl PE, namely
Amadori-PE.
Fig. 2. E¡ects of Amadori-PE on HUVEC proliferation. A: HU-
VEC were cultured for 72 h in the absence (F) or presence of either
1 WM Amadori-PE (a) or 1 WM non-glycated dioleoyl-PE (b). HU-
VEC were also incubated with various doses of Amadori-PE for
36 h (B) or 72 h (C). At each time point, the number of viable cells
was estimated by the WST-1 assay. *Signi¢cant di¡erence compared
to control cells (P6 0.05). Values are meanTS.D. of six wells. Rep-
licate experiments (at least three times) demonstrated a similar
trend.
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closure observed over the following 12 h. In cultures supple-
mented with 5 WM Amadori-PE, endothelial cells migrated
into the denuded area, recovered the exposed surface, and
reduced the uncovered area (Fig. 3A). A slight increase in
the rate of wound closure was observed with the addition of
1 WM Amadori-PE (Fig. 3A,B). Such migratory activity was
not observed in the non-glycated dioleoyl-PE-treated cells
(Fig. 3A).
We then examined the e¡ect of Amadori-PE on tubular
morphogenesis of endothelial cells. When HUVEC were co-
cultured with human ¢broblasts and incubated for 11 days
with 10 ng/ml of VEGF, an increase in the number of tube-
like structures was observed (Fig. 4A). Amadori-PE, like
VEGF, was found to enhance the width and length of the
endothelial tubes (Fig. 4A), with this e¡ect being maximal
at 5 WM Amadori-PE and approximately 1.7-fold higher
than untreated control cells (Fig. 4B). Addition of non-
glycated PE did not a¡ect the basal level of tube formation
(Fig. 4A).
These results indicated Amadori-PE enhanced several in
vitro endothelial cell activities that are relevant to angiogene-
sis, including proliferation, migration and tube formation. We
next evaluated the mechanism of Amadori-PE-driven angio-
genesis in vitro by measuring the secretion of well-character-
ized angiogenic factors such as VEGF and MMPs. ELISA
analysis of VEGF and MMP-1, MMP-2 and MMP-9 revealed
that Amadori-PE over the concentration range 1^5 WM re-
sulted in upregulation of MMP-2 secretion from HUVEC in
a dose-dependent manner (Fig. 5A). Amadori-PE has no sig-
ni¢cant e¡ect on MMP-1, MMP-9 and VEGF secretion from
HUVEC although there was a slight increase in MMP-9 se-
cretion (Fig. 5A). To determine the e¡ect of Amadori-PE on
MMP-2 secretion in greater detail, we carried out a zymogram
analysis that enabled us to visualize gelatinolytic activity of
the secreted proteinase. As shown in Fig. 5B, the results of the
ELISA assay were con¢rmed by zymography. In addition,
treatment of HUVEC with 1^5 WM Amadori-PE signi¢cantly
enhanced MMP-2 mRNA expression (Fig. 5C), with this ef-
fect being maximal at 5 WM.
Fig. 3. E¡ects of Amadori-PE on HUVEC migration. A: A con£u-
ent HUVEC monolayer was sheared with a yellow pipette tip, fol-
lowed by exposure to a fresh medium containing Amadori-PE (0^5
WM), or 5 WM dioleoyl-PE. After 12 h, closure of the wound was
observed using a phase contrast inverted microscope. B: Each well
was observed in four randomly chosen ¢elds, and the width of
wound measured. *Signi¢cant di¡erence compared to control
(P6 0.05). Values are meanTS.D. of six wells. Replicate experi-
ments (at least three times) demonstrated a similar trend.
Fig. 4. E¡ects of Amadori-PE on tube formation in HUVEC.
A: HUVEC co-cultured with ¢broblasts were cultured in the ab-
sence (control) or presence of test samples (5 WM Amadori-PE and
5 WM dioleoyl-PE) for 11 days. VEGF (10 ng/ml) was tested under
identical conditions as a positive control. B: Tube formation was
observed in four randomly chosen ¢elds, and the tube lengths mea-
sured. *Signi¢cant di¡erence compared to control (P6 0.05). Values
are meanTS.D. of six wells. Replicate experiments (at least three
times) demonstrated a similar trend.
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4. Discussion
In this study we investigated the in vitro angiogenic e¡ects
of Amadori-PE, a non-enzymatically glycated lipid formed
under hyperglycemic conditions, on endothelial cells. This se-
ries of experiments included measuring the growth, migration
and tube formation of HUVEC under a variety of culture
conditions. To date there has been no study on the physio-
logical activity of Amadori-PE with the exception of one re-
port that showed it induced lipid peroxidation in vitro [17].
Several recent in vivo and in vitro studies have shown that the
formation and accumulation of AGEs is proportional to
aging and the severity of diabetic complications and that these
changes promote angiogenesis [10^12]. These results led us to
hypothesize that lipid glycation products may also induce an-
giogenic di¡erentiations.
We found that proliferation and migration of HUVEC were
enhanced to a moderate extent by treatment of Amadori-PE
in a dose- and time-dependent manner (Figs. 2 and 3). Fur-
thermore, Amadori-PE increased the formation of capillary-
like networks by the HUVEC (Fig. 4). In contrast, exposure
to dioleoyl-PE, a non-glycated PE, caused no change in an-
giogenic di¡erentiation. This indicated that the angiogenic
action was speci¢c to the glycated lipid, but not to intact
lipids. Amadori-PE over the concentration range 1^5 WM re-
sulted in the maximal e¡ect in all cases (Figs. 2^4). Ravandi et
al. [14] reported that the mean Amadori-PE level in plasma
from patients with diabetes was 4.8% per mg of phospholip-
ids, equivalent to approximately 50 Wg/ml of plasma. The
concentration range of Amadori-PE of 1^5 WM that we
used in our in vitro experiments for the evaluation of endo-
thelial di¡erentiations was therefore comparable to the con-
centration of this lipid in the plasma of patients with diabetes.
It is well known that VEGF is one of most potent factors
for accelerating angiogenesis. Recently, Yamagishi et al. [11]
suggested that angiogenic activity of AGEs on endothelial
cells was mediated mainly by induction of autocrine vascular
VEGF. In order to con¢rm whether Amadori-PE also stimu-
lated the release of VEGF from HUVEC, we determined
whether VEGF proteins were present in the conditioned me-
dium using ELISA. However, we were unable to con¢rm clear
secretion of VEGF from the HUVEC regardless of the addi-
tion of Amadori-PE or non-glycated PE (Fig. 5A). This sug-
gested that the enhancing e¡ect of Amadori-PE on angiogen-
esis in endothelial cells was not attributable to autocrine
vascular VEGF.
An initial step in the angiogenic process is the degradation
of subendothelial basement membrane and surrounding extra-
cellular matrix (ECM) [22]. Following matrix breakdown, en-
dothelial cells migrate and proliferate to form new vessels.
Proteolytic enzyme activity degrading ECM is therefore essen-
tial for the initial angiogenesis process. The MMPs, a family
of Zn2þ-dependent endopeptidases, are responsible for the
digestion of a variety of ECM components [23]. Endothelial
cells express various MMPs, including MMP-1 (collagenase),
MMP-2 (gelatinase A) and MMP-9 (gelatinase B) [24].
Although the contribution of MMPs to angiogenesis has
been attributed primarily to their ability to break down the
ECM, they also have the ability to promote migration and
proliferation of endothelial cells [25,26]. Given this important
role of MMPs in angiogenesis we measured the concentration
of MMP-1, MMP-2 and MMP-9 in conditioned medium of
HUVEC using ELISA. We found the secretion of MMP-2
from the HUVEC was signi¢cantly enhanced when the cells
were exposed to Amadori-PE (Fig. 5A). This result was re-
£ected by increases in both enzymatic activity (Fig. 5B) and
mRNA levels (Fig. 5C).
It has been suggested that Amadori-PE may be present in
atherosclerotic lesions of individuals with diabetes [27]. We
have shown previously that Amadori-PE may be an origin
compound for generating reactive oxygen species [17]. A re-
cent study demonstrated MMPs were activated by reactive
oxygen species, and were implicated in atherosclerotic plaque
stability associated with diabetic complications [28]. There-
fore, the elevation of MMP-2 secretion which we observed
following addition of Amadori-PE (Fig. 5) also provides a
possible mechanism to account for the adverse changes in
MMP activity that occur in diabetic atherosclerosis.
Under long-term hyperglycemia, early stimuli elicit adaptive
reactions of tissues showing acute in£ammatory processes of
vessel walls and then late irreversible changes of microangi-
opathy [29]. The mechanisms of how these changes occur
remain speculative; increased polyol pathway, excessive for-
Fig. 5. E¡ect of Amadori-PE on the secretion of MMPs and VEGF
from HUVEC. A: HUVEC were cultured in the absence (control)
or presence of test samples (0.25^5 WM Amadori-PE and 5 WM dio-
leoyl-PE) for 24 h. The culture medium was then harvested and the
yields of MMPs and VEGF in the medium measured by ELISA as
described in Section 2. *Signi¢cant di¡erence compared to control
(P6 0.05). Values are meanTS.D. of six wells. Replicate experi-
ments (at least three times) demonstrated a similar trend. B: HU-
VEC were exposed to Amadori-PE (0.25^5 WM) or 5 WM di1oleoyl-
PE for 24 h. The MMP-2 released from the HUVEC into the me-
dium was analyzed by zymography. C, control (without test sam-
ple); PE, dioleoyl-PE. C: HUVEC were incubated with Amadori-
PE (0.25^5 WM) or 5 WM dioleoyl-PE for 24 h. The level of MMP-
2 mRNA in the HUVEC was then measured using an RT-PCR
method as described in Section 2. M, DNA marker; P, positive con-
trol; C, control (without test sample); PE, dioleoyl-PE.
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mation of AGEs, increased protein kinase C activity, and
oxidative stress are all interrelated for the cause and develop-
ment of the microangiopathy [30]. Focusing on AGEs, it is
reported that AGEs promote vascular cell changes typical of
diabetes, including angiogenic and thrombogenic responses of
endothelial cells, and pericyte loss [31]. Thus, our future aim is
to explore whether Amadori-PE also has these abnormal
properties.
To date, although a number of studies [10^12] have sug-
gested a relationship between glycation and angiogenesis,
there is no information on the potential interactions between
lipid glycation and angiogenesis. In this study, Amadori-PE, a
lipid glycation product, stimulated the growth, migration and
tube formation of HUVEC in a dose-dependent manner.
Hence, Amadori-PE may be one of the important inducers
of angiogenesis in vivo. Now, this possibility is being inves-
tigated with in vivo angiogenesis models (i.e. chick embryo
chorioallantoic membrane assay).
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